Clinical trials in nuclear medicine. Sorted by date of last update.
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu-177 Dotatate) for Pancreatic Neuroendocrine Tumors
Phase 1
Last update: December 12
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
Phase 2
Testing Lutetium Lu-177 Dotatate in Patients with Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients with Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH
Phase 4
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Last update: December 11
Lu-177-DOTA-EB-TATE in Adult Patients with Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
A Prospective Observational Study on Efficacy of TARE for Early Stage HCC (KURE-YTT-HCC)
N/A
Phase I Study of [Lu-177]Lu-NNS309 in Patients with Pancreatic, Lung, Breast and Colorectal Cancers
Observational Study on Lutetium (Lu-177) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer
Lu-177-DOTATATE (Lutathera) in Combination with Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)